References in periodicals archive ?
Limited Tenders are invited for Purchase Of Medicines Inj Peginterferon beta-1a (Plegridy 125 micrograms) Qty 02 PFS.
Peginterferon beta-1a, a pegylated form of interferon beta-1a, is currently in phase III clinical trials for relapsing MS and has the potential to improve patient compliance by reducing the number of injections while maintaining clinical efficacy.
Rationale for and Clinical Development of Peginterferon Beta-1a for MS
Pegylated interferon beta compounds in development as therapies for RMS include peginterferon beta-1a (Biogen Idec, Inc.
Peginterferon beta-1a has completed both preclinical testing (Hu et al.
Two phase I clinical studies of peginterferon beta-1a have been reported: a single-dose study (n = 60) comparing SC and im injections of peginterferon beta-1a (63, 125, and 188 [micro]g) with unmodified im interferon beta-1a of 30 [micro]g and a multiple-dose study (n = 69) comparing SC peginterferon beta-1a injected every 2 or 4 weeks with placebo (Hu et al.
Results support peginterferon beta-1a as a potential treatment dosed every two weeks or every four weeks for relapsing-remitting multiple sclerosis (RRMS).
Results showed that peginterferon beta-1a also met the secondary endpoints of risk of 12-week confirmed disability progression, proportion of patients who relapsed and magnetic resonance imaging (MRI) assessments for both dose regimens.
If approved, peginterferon beta-1a will represent an innovation that offers patients a less frequent dosing schedule of no more than 26 doses annually, as well as a significant reduction in relapses and disability progression," said Gilmore O'Neill, vice president, Global Neurology Late Stage Clinical Development at Biogen Idec.
The ADVANCE study included more than 1,500 patients with RRMS and was designed to evaluate the efficacy, safety and tolerability of peginterferon beta-1a compared to placebo at one year.
Contract award notice: Therapeutic program - thyflunomide, Peginterferon beta-1a.
Package number 1 teryflunomide film-coated tablets; 14 mg x 28 tablets, 260 op package number 2 peginterferon beta-1a solution for injection in pre-filled pens - starter (63 micrograms + 94 micrograms), 10 op peginterferon beta-1a solution for injection in pre-filled pens; Dose of 125 micrograms 120 op.